Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Article Title: DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.

PMID/MRN: 27749128

Publication Date: 2016-Oct-17

Abstract:

The purpose of the present study was to investigate the predictive factors for worse disease-specific survival in patients with pulmonary disease secondary to differentiated thyroid cancer. This was a retrospective cohort study conducted over a 5-year period that included 54 patients with pulmonary disease secondary to DTC during the follow-up. Among these patients, 13 (24.1%) died from the disease. Dedifferentiation characteristics were identified at pathological examination of the metastatic disease (lymph node or distant metastases), and was defined as the abrupt transformation of a well-differentiated tumor into high grade morphology that lacks the original distinct histologic characteristics. Tumor dedifferentiation marked by cellular aberrations and radioiodine therapy resistance occurred in 5 patients (9.3%). Four of these patients died due to pulmonary progression (80.0%), and the median survival of this group was 30 months compared to 279 months in the patients without dedifferentiation. The cumulative disease-specific survival was 20.0% in the patients with dedifferentiation during the follow-up versus 46.1% among the cases without this condition (P=0.003; log-rank test). Moreover, dedifferentiation was independently associated with a worse disease-specific survival (HR=31.607; CI95%: 4.815-207.478; P<0.0001, Cox regression model) as were an age over 45 years (HR=10.904; CI95%: 1.145-103.853; P=0.038) and the male gender (HR=4.210; CI95%: 1.056-16.783; P=0.042). DTC patients with pulmonary disease exhibited worse disease-specific survival, particularly those who developed tumor dedifferentiation, and these patients require special attention during follow-up.